文献速递消化内镜消化道肿瘤与早癌

瑞巴派特溶液:一种促进内镜黏膜下剥离术所致溃疡愈合速度与质量的新型黏膜下注射材料

Rebamipide solution: a novel submucosal injection material to promote healing speed and healing quality of ulcers induced by endoscopic submucosal dissection.
PubMed 文献 · Gastrointest Endosc · 2017-10-06

本研究在8只猪胃内应用2%瑞巴派特溶液与生理盐水作为黏膜下注射材料行内镜黏膜下剥离术(ESD),比较技术结局并每周内镜评估溃疡愈合评分至4周。结果显示两组技术结局无显著差异,瑞巴派特组在第2、3、4周愈合评分显著高于对照组,第2、4周纤维化显著少于对照组。

要点

  • 瑞巴派特溶液与生理盐水在ESD技术结局上无显著差异,未见相关不良事件。
  • 瑞巴派特组溃疡愈合评分在第2、3、4周显著高于对照组。
  • 瑞巴派特组纤维化在第2、4周显著少于对照组。

核心结论

  • 瑞巴派特溶液似乎通过抑制纤维化促进ESD所致溃疡的愈合速度与质量。

研究设计与样本

  • 在体猪模型研究,8只猪胃内行模拟30 mm病变的ESD,每位术者对测试药剂设盲。
  • 每只猪2处使用2%瑞巴派特溶液(瑞巴派特组),另2处使用生理盐水(对照组)。
  • ESD后每周内镜评估胃溃疡分期共4周以确定愈合评分(1-6)。
  • 猪分别于ESD后1周(n=2)、2周(n=2)、4周(n=4)处死以进行病理评估。

主要发现

  • 两组间任何技术结局均无显著差异,所有动物均无与ESD相关的不良事件。
  • 愈合评分瑞巴派特组在2周(P=.027)、3周(P=.034)、4周(P=.012)显著高于对照组。
  • 组织病理学评估中,纤维化瑞巴派特组在2周(P=.02)和4周(P=.04)显著少于对照组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Rebamipide is administered perorally to protect the gastric mucosa. We assessed the efficacy and safety of a novel rebamipide solution as a submucosal injection material for endoscopic submucosal dissection (ESD) using an in vivo porcine model. METHODS: An endoscopist blinded to the test agents performed ESDs of hypothetical 30 mm lesions using a 2% rebamipide solution at 2 sites (rebamipide group) and a saline solution at 2 other sites (control group) in the stomachs of 8 pigs. The technical outcomes were compared between the 2 groups. The gastric ulcer stages were evaluated by endoscopy once weekly for 4 weeks after the ESD to determine the healing score (1-6). The pigs were killed at 1 week (n = 2), 2 weeks (n = 2), and 4 weeks (n = 4) after the ESD for pathologic evaluation of ESD-induced ulcers and scarring. RESULTS: There were no significant differences in any of the technical outcomes between the 2 groups, and no adverse events related to the ESD in any of the animals. The healing score was significantly higher in the rebamipide group than in the control group at 2 weeks (P = .027), 3 weeks (P = .034), and 4 weeks (P = .012). In the histopathologic assessment, fibrosis was significantly less extensive in the rebamipide group than in the control group at 2 weeks (P = .02) and 4 weeks (P = .04). CONCLUSIONS: The rebamipide solution appeared to promote both the speed and quality of healing of ESD-induced ulcers by suppressing fibrosis.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Fujimoto A, Uraoka T, Nishizawa T, et al. Rebamipide solution: a novel submucosal injection material to promote healing speed and healing quality of ulcers induced by endoscopic submucosal dissection. Gastrointest Endosc. 2017. PMID: 28993136. doi:10.1016/j.gie.2017.09.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。